MedTrace Logo

Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations

NCT04360226 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-04-10

No results posted yet for this study

Summary

This is an international, mulitcentre, observational, prospective study into Peak Inspiratory Flow in COPD patients that aims to: A) Determine the prevalence of suboptimal Peak Inspiratory Flow (PIF) and inadequate inhaler choice and assess the baseline characteristics of these groups. B) Assess the clinical role of PIF and inhaler choice in predicting COPD exacerbations and symptom burden. C) Assess the variability and correlation of PIF with other lung function measurements and CAT score in stable COPD. It is a 12 month study comprising one baseline assessment and 2 follow-up visits at 6 and 12 months.

Conditions

Interventions

OTHER

Non-interventional

Non-interventional, subjects will only have routine testing (blood biomarkers, spirometry, peak inspiratory flow measurements) and be asked to complete questionnaires.

Sponsors & Collaborators

Principal Investigators

  • Omar Usmani, MD · National Heart and Lung Institute, Imperial College London & Royal Brompton Hosp

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-14
Primary Completion
2023-08-01
Completion
2024-01-25

Countries

  • Italy
  • Malta
  • Singapore
  • Slovenia
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04360226 on ClinicalTrials.gov